Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ba54b0c53b65e8653f626cf6d3e5ddf http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75f2f6f907d50ec62005a4a4a3eee673 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-32722 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-125 |
filingDate |
1988-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2000-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea769f9f5db129c962830042e54adcd3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c0365e3c65cdae3bd12216f5e9f807b |
publicationDate |
2000-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-1340926-C |
titleOfInvention |
Human rhinovirus peptides |
abstract |
A synthetic peptide, suitable for use as a vaccine against a human rhinovirus (HRV), presents an epitope comprising amino acid residues 156 to 164 of VP2 of HRV type 2 or equivalent amino acid residues of another HRV. Optionally one or more of the acid residues may be replaced by one or more other amino acid residues which do not affect the antigenicity of the peptide. |
priorityDate |
1987-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |